Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Boston Therapeutics, Inc.
MANCHESTER, N.H., Dec. 10, 2013 /PRNewswire/ -- Sometimes people have to be protected from their own bad habits. For example, in 2012, a national sandwich chain offered its cinnamon roll lovers a change: they replaced the 550-calorie version with a 480-calorie version by removing the sugar glaze. The outcry was immediate. The company was inundated with emails "lamenting the loss of the sweet goo," according to Bloomberg Businessweek. Two months later, the glazed rolls were back, Bloomberg reported.
Food companies and restaurants are faced with a choice: Either give people what they want -- which is good for business and keeps investors happy -- or withhold unhealthy items, which can quickly lead formerly loyal customers to flock to a competitor.
Now there just might be a solution to this conundrum. Boston Therapeutics, Inc., based in Manchester, NH, is focusing on Type 2 diabetes patients -- of which there are 25.8 million people in the U.S., according to the American Diabetes Association.
Boston Therapeutics is working on a product called PAZ320: a chewable, complex carbohydrate-based compound designed to reduce blood sugar in Type 2 diabetes patients taking metformin. In other words, by "blocking" sugar from the bloodstream, PAZ320 may, if proven safe and efficacious in clinical studies, help Type 2 diabetes patients.
As David Platt, Ph.D., CEO of Boston Therapeutics, explains, "In an ideal world, we'd all do right by ourselves. Type 2 diabetes patients need help managing their glucose levels, and we designed PAZ320 to help them do exactly that."
In a Phase IIa study last year at Dartmouth-Hitchcock Medical Center in Lebanon, NH, 45 percent of Type 2 diabetes patients taking metformin responded to PAZ320 with a 40 percent reduction of post-meal glucose in the blood -- i.e. post-meal glucose elevation was cut almost in half.
For more, visit www.bostonti.com, who paid for the writing and dissemination of this release.
Contact: Laura Radocaj, Dian Griesel Int'l.
©2012 PR Newswire. All Rights Reserved.